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Background and purpose   Postoperative analgesia after primary 
total  hip  arthroplasty  (THA)  using  opioids  is  associated  with 
troublesome side effects such as nausea and dizziness, and epi-
dural analgesic means delayed mobilization. Thus, local infiltra-
tion analgesia (LIA) during surgery prolonged with local infusion 
analgesia (LINFA) into the soft tissue in the hip region through 
a catheter in the first postoperative days has gained major inter-
est in THA fast-track settings within a short period of time. LIA 
at the time of surgery is a validated treatment. We investigated 
the additional effect of giving postoperative LINFA after THA in 
patients already having LIA during surgery. 
Patients and methods   60 consecutive patients undergoing non-
cemented THA were randomized into two groups in a double-
blind and controlled study. During surgery, all patients received 
standardized  pain  treatment  with  LIA.  Postoperatively,  they 
were treated either with a solution of Ropivacain, Ketorolac, and 
Adrenaline (LINFA group) or placebo (placebo group) adminis-
tered through a catheter to the hip 10 and 22 h after surgery. Pain 
score, opioid consumption, and length of stay (LOS) were evalu-
ated.  
Results   After adjustment for multiple testing, there was no sta-
tistically significant postoperative difference between the LINFA 
group and the placebo group regarding pain and tiredness. We 
found some evidence of a short-term effect on nausea and vomit-
ing. Opioid consumption and length of stay were similar in the 
two groups. 
Interpretation   We found some evidence of a short-term effect 
of LINFA on nausea and vomiting, but no evidence of an effect on 
postoperative pain and tiredness. Thus, LINFA cannot be recom-
mended as a standard pain treatment in patients with THA.
 
In Denmark, the waiting time for total hip arthroplasty (THA) 
early in the last decade was more than 1 year. To increase 
the numbers of surgeries, several hospitals focused on  early 
mobilization and early discharge. Because of this, periopera-
tive pain treatment gained major attention as the most impor-
tant factor (Kehlet and Dahl 2003, Rostlund and Kehlet 2007). 
Postoperative pain in THA has traditionally been managed 
with epidural analgesia (Choi et al. 2003), with peripheral 
nerve blocks, or solely with opioid drugs (Fischer and Siman-
ski 2005). Opioids are well known to be associated with trou-
blesome side effects such as nausea, vomiting, and dizziness, 
and  epidural  analgesic  is  associated  with  urinary  retention 
and delayed mobilization. Thus, neither opioids nor epidural 
pain treatment are attractive as a treatment modality in units 
focusing on fast rehabilitation after THA. The next generation 
of analgesia regimes in THA, with reduced or minimal side 
effects while maintaining adequate pain relief and maximum 
muscle control, is therefore of considerable interest.  
Local infiltration analgesia (LIA) was presented by Kerr and 
Kohan of the Joint Orthopaedic Center in Sydney, Australia, 
in 2005 (Kerr and Kohan 2008). They reported a multimodal 
technique including LIA as pain relief in a fast-track setting 
after total hip and knee replacement. In their intraoperative set-
up, soft tissues around the surgical field were infiltrated with 
a mixture of Ropivacaine, Ketorolac, and adrenaline, followed 
by LINFA through a catheter after 20 h. In a non-randomized 
study, they reported effective pain relief with early mobiliza-
tion and reduced length of stay (LOS) (Kerr and Kohan 2008).
Three other publications have presented pain results after 
LIA in THA (Bianconi et al. 2003, Andersen et al. 2007a, b). In 
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Bianconi et al. showed intraoperative LIA in combination with 
postoperative LINFA with Ropivacaine to be superior to intra-
venous infusion of morphine and Ketorolac postoperatively 
(Bianconi et al. 2003). In a randomized, double-blind study, 
Andersen et al. (2007a) showed intraoperative infiltration with 
a mixture of Ropivacaine, Ketorolac, and adrenaline into the 
deep tissue in the wound followed after 8 h by intraarticular 
LINFA with the same mixture through a catheter to be more 
effective than continuous epidural infusion with Ropivacaine 
and morphine. Finally, in a randomized, double-blind study 
Andersen et al. (2007b) found intraoperative LIA with a mix-
ture of Ropivacaine, Ketorolac, and adrenaline combined with 
postoperative LINFA using same mixture through a catheter 
in the hip joint to be substantially more effective than saline 
administered both intraoperatively and postoperatively. 
Within a short period, LIA during surgery combined with 
LINFA into the soft tissue in the hip region through a cath-
eter in the first postoperative days has gained major interest in 
fast-track THA settings. However, there is no evidence from 
the existing literature of there being any extra benefit from 
adding  postoperative  LINFA  in  patients  who  have  already 
been treated with LIA during surgery.
We investigated whether there was any additional effect of 
LINFA  administered  postoperatively  through  a  catheter  on 
pain and opioid consumption over the first 24 h, and its effect 
on length of hospital stay after THA in patients already treated 
with LIA during surgery.
Patients and methods
The study protocol was approved by the Ethics Review Board 
of Southern Denmark (June 22, 2007, ID S-20070066) and 
the Danish Drug Agency (EudraCT no. 2007-003890-20). It 
was  registered  with  ClinicalTrials.gov  (ID  NCT00603083) 
and conducted in accordance with the Declaration of Helsinki. 
After written informed consent was obtained, 60 consecutive 
patients over 18 years of age with osteoarthritis of the hip, 
who were scheduled for uncemented unilateral THA, were 
enrolled.  Primary  exclusion  criteria  were:  anterior  surgical 
approach, use of navigation equipment during surgery, known 
allergy or intolerance to one of the study drugs, simultane-
ous bilateral THA, general anesthesia, regular use of opioids, 
inability to comprehend pain scales, women of fertile age, an 
American Society of Anesthesiologists (ASA) classification 
of III or more, medication with lithium, dihydroergotamine 
or anticoagulants, active peptic ulcer, hemorrhagic diastase, 
gastrointestinal bleeding, severe thrombocytopenia, bleeding 
disorders, asthma, severe liver or heart disease, hypertension, 
or thyrotoxicosis. 
Surgery was performed at the Department of Orthopaedic 
Surgery, Vejle Hospital, from January, 2008 through October, 
2008, and for this study patients were followed for 7 days after 
surgery.
Randomization and blinding
The study design was a randomized, double-blind and pla-
cebo-controlled clinical trial. The randomization was carried 
out  by  an  external  dispensary  using  a  computer-generated 
second-generation randomization with 10 blocks of 6 patients 
each (www. randomization.com). The allocation outcome was 
concealed from the patients, the surgeons, and all healthcare 
providers,  data  collectors,  assessors  of  outcome,  and  stat-
isticians (Haahr and Hrobjartsson 2006). On the day of sur-
gery, the patients were randomized to receive either LINFA 
or placebo by using sequentially numbered medicine bottles 
produced and labeled by the external dispensary. The alloca-
tion outcome was concealed until all results were observed, 
recorded, and analyzed. During this period, the groups were 
named A and B.
Anesthesia
All patients had their hips operated using a combined spinal 
anesthesia (1.5 mL Bupicaine 0.25% + 1.5 mL saline at L2/3 
or L3/4, 25 gauge, Quincke tip) and light general anesthesia (a 
combination of Propofol and Ketamine infusion). If there was 
airway obstruction, a laryngeal mask airway was used.
Surgery
All operations were performed by one of 4 surgeons using 
a posterolateral approach. The same surgical technique was 
used in both groups, including absence of suction drainage 
from the wounds. 
Pain treatment
On the morning of surgery, Paracetamol Retard (2 g) was given 
orally to both groups as premedication. During surgery, all 
patients in both groups received a standardized pain treatment 
with LIA (200 mg Ropivacaine (2 mg/mL), 30 mg Ketorolac 
(30 mg/mL), and 1 mg adrenaline (1mg/mL)) as a total solu-
tion of 102 mL, which was divided into in 2 injections. After 
implanting the acetabular component, the first 51 mL of LIA 
was injected; the second injection of 51 mL was given after 
reinsertion of the rotator muscles. Standardized techniques for 
the injection were used, with the first dose being given mainly 
in the anterior and inferior joint capsule, and the lesser gluteal 
muscle. The second dose was administered to the medius and 
maximus gluteal muscle and the lesser rotators. All patients 
had  a  tunneled  intraarticular  multi-hole  catheter  placed  by 
the surgeon at the end of surgery. As postoperative oral pain 
treatment,  all  patients  received  1  g  Paracetamol  4  times  a 
day, starting in the post-anesthesia care unit, and Ibuprofen 
400 mg 4 times a day, starting in the morning after the opera-
tion. Oxycodone (5 mg) was used as patient-controlled rescue 
medication. After 10 and 22 h, 51 mL of the same solution as 
used during surgery was injected intraarticularly through the 
catheter in the LINFA group. In the placebo group, a similar 
volume of saline was injected at that same time. All patients 
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Outcome measures
Opioid consumption was registered by the patients themselves 
followed by a check by the nurse on duty. Consumption was 
recorded during the first 72 h after surgery. For an overall 
evaluation, narcotics were converted to morphine equivalents 
(Schug and Gandham 2006).
Pain was evaluated by using a self-reported questionnaire: 
Western  Ontario  MacMaster  Universities  (WOMAC  verbal 
rating scale) osteoarthritis index (Bellamy et al. 1988) score 
for pain preoperatively, as primary endpoints at 12, 22, and 
24 h postoperatively, and after that as secondary endpoints at 
8 a.m. and 8 p.m. until day 3 after surgery. The last endpoint 
for pain scores was 7 days after surgery. In addition, until day 
7 at those same time points, the numerical rating scale (NRS 
0–10) was used for pain score at rest and during activity (first 
12 h after surgery: trying to raise leg from the mattress; after 
12 h: walking).
Postoperative nausea and vomiting (PONV). NRS (0–10) 
and 3 items from the European Organization for Research and 
Treatment of Cancer (EORTC) QLQ-C30 (Sprangers et al. 
1993) were used to score PONV at 8 p.m. on days 0–3 after 
surgery.
Tiredness. NRS (0–10) and 3 items from the Nottingham 
Health Profile (NHP) (Hunt et al. 1986, Thorsen et al. 1993) 
were used for assessment of tiredness preoperatively and at 8 
p.m. on days 0–3 after surgery. 
LOS. The day of surgery was defined as day 0. The patients 
were discharged when they had fulfilled the following criteria: 
walking with elbow crutches, ability to climb stairs, and no 
evidence of any surgical complications. 
All complications and adverse events were registered intra-
operatively, postoperatively and after discharge. 
Statistics
A power analysis was done before the start of the study using 
Oxycodone consumption as the primary endpoint. With an a 
of 0.05 and a β of 0.2, we expected a reduction in Oxycodone 
from 38 mg to 19 mg in the treatment group. This 50% reduc-
tion in opoid consumption was regarded as a relevant clini-
cally significant effect, and was used as the primary endpoint. 
With a standard deviation of 23 mg, 22 patients were needed 
in  each  group. Assuming  that  there  would  be  a  somewhat 
greater standard deviation in the control group, we decided to 
include 30 patients in each group.
Rasch  analyses  (Rasch  1960)  were  conducted  on  the 
WOMAC  pain  scale  and  the  2  NRS  pain  items,  on  the  3 
nausea items from the EORTC plus the nausea NRS, and on 
the 3 energy items from the NHP plus the tiredness NRS. 
The Rasch analyses included examination of dimensionality, 
local response dependencies, and differential item functioning 
(DIF). Fit to the Rasch model was estimated by comparing 
the observed and expected responses for each item evaluated 
by  conditional  likelihood  ratio  chi-square  test.  Conditional 
likelihood ratio chi-square test was also used for overall tests 
of DIF. The tests were done both for the partial credit Rasch 
model and for the log-linear Rasch model (Kreiner and Chris-
tensen 2007, Kreiner 2007).
For each of the 3 constructs, all items fitting the Rasch model 
were used to obtain the most valid and reliable measurement 
of pain, nausea, and tiredness. Inclusion of all Rasch-fitting 
items would cover the latent trait measured with most response 
categories from the polytomous items included in the dimen-
sions. In this way, maximum achievable valid information of 
each construct was ensured.
Data were analyzed with an intention-to-treat approach. The 
Mann-Whitney U test was used for analysis of both the pri-
mary and secondary endpoints, since the data were not nor-
mally distributed. Results are presented as frequency (%) or 
median (range). Any p-values of < 0.05 were considered to be 
statistically significant.
Results
Item analysis by graphical log-linear Rasch models 
Pain measurement. There was strong evidence of local depen-
dence between the WOMAC items 1 and 7, 2 and 3, 4 and 
6, and 5 and 6. There was little and inconsequent evidence 
of DIF among the WOMAC items. All WOMAC items fitted 
the log-linear Rasch model. The local dependence among sev-
eral of the items meant that the reliability was lower than sug-
gested by Cronbach’s alfa (a = 0.94, true reliability = 0.90). 
The two NRS pain items measured the same latent trait as the 
WOMAC pain scale (expected pain score = 0.730, observed 
pain score = 0.738, p = 0.6 by chi-squared test) with no further 
local response dependency and DIF revealed. All WOMAC 
items plus the two NRS items therefore appeared to be prefer-
able for measurement of pain.
Nausea measurement. Tests of the conditional likelihood 
ratio comparing item parameter estimates in different subpop-
ulations defined by total scores on the EORTC nausea scale, 
by different time points and by values of exogenous covari-
ates, revealed evidence against the Rasch models (c2 = 17.7, 
df = 8, p = 0.02). No DIF among the 3 EORTC items was 
revealed; however, items 1 and 2 were locally dependent. The 
log-linear  Rasch  model  perfectly  predicted  the  strength  of 
the association between EORTC items and rest scores (Table 
1, see supplementary data). Adding the NRS nausea item to 
the scale did not change anything: no DIF, but local depen-
dence between the first 2 items. The reliability of the 3-item 
scale was 0.81. The reliability of the global item was 0.88. All 
EORTC items plus the NRS items therefore appeared to be 
preferable for measurement of nausea.
Tiredness measurement. No evidence of local dependency 
among the 3 NHP energy items was revealed and there was no 
evidence against the Rasch models. However, comparison of 
separate NHP items over time and across age groups disclosed 
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and of item 3 relative to time of measurement (p < 0.001). 
The DIF relative to time is particularly disturbing, since it will 
confound measurement of the general energy levels over time 
if this is disregarded. 
The fit of the 3 NHP items and the NRS tiredness item to 
the partial credit model was acceptable, except that the DIF 
for the 2 above-mentioned NHP items reappeared. Assess-
ment of reliability of the 3-NHP-item scale was r = 0.76 while 
the reliability of the global question was r = 0.94. For these 
two reasons, the global question appeared to be preferable for 
measurement of tiredness.
Patients
Of  the  60  patients  enrolled  in  the  study,  4  in  the  placebo 
group and 2 in the LINFA group discontinued the interven-
tion (Figure, see supplementary data). In the placebo group, 2 
patients did not receive the second postoperative intraarticular 
injection, one by mistake and the other because the patient 
did not want it. 2 other patients in the placebo group did not 
receive any of the 2 intraarticular injections due to a blocked 
catheter. In the LINFA group, 2 patients did not receive either 
of the 2 postoperative intraarticular injections: 1 had a blocked 
catheter and the other had general anesthesia and did not get a 
catheter. Data from all 60 patients were analyzed (Figure, see 
supplementary data). 
The  placebo  group  had  more  females  (60%)  than  the 
LINFA group (33%), and the patients in the placebo group 
were older with less function than the patients in the LINFA 
group (Table 2). The 2 groups were similar regarding body 
mass index, living with a partner, ASA classification, pre-
operative pain level, duration of surgery, and intraoperative 
bleeding (Table 2).
Consumption of opioids
During the first 24 h after surgery, no statistically significant 
difference in opioid consumption was observed between the 2 
groups (p = 0.5). In all other measured periods until day 7, no 
significant difference was observed (Table 3, see supplemen-
tary data).
Postoperative pain
After adjustment for multiple testing, there was no statistically 
significant difference between the LINFA group and the pla-
cebo group regarding postoperative pain (Tables 4 and 5, see 
supplementary data). 
Adverse effects
On days 1 and 2 after surgery, there were higher incidences of 
nausea and vomiting in the placebo group than in the LINFA 
group (Table 6). After adjustment for multiple testing, there 
was no statistically significant difference between the LINFA 
group and the placebo group regarding tiredness postopera-
tively (Table 6).
None of the 60 patients had any evidence of a prosthesis 
infection. 1 patient in the placebo group was treated with anti-
biotic because of prolonged wound drainage. 
LOS
The study showed a trend of shorter LOS in the LINFA group 
(median 3 (2–6) days) than in the placebo group (median 3 
(2–7) days) but the difference was not statistically significant 
(p = 0.09).
Table 2. Patient characteristics for the LINFA and placebo group
  LINFA group  Placebo group
  (n = 30)  (n = 30)
Age, years a   64 (54–78)  68 (54–82)
Female, n (%)  10 (33%)  18 (60%)
Body mass index a   27 (19–37)  28 (20–37)
Living with partner, n (%)  24 (80%)  25 (83%)
ASA classification, n (%)
  I (normal healthy)    8 (27%)  11 (37%)
  II (mild systemic disease)  22 (73%)  19 (63%)
Preoperative pain level a
  WOMAC   13.0 (1–20)  13.0 (4–18)
  NRS (rest + activity)    7.5 (0–16)    9.0 (0–15)
  WOMAC + NRS (rest + activity)  20.5 (2–34)  22.0 (6–31)
Preoperative WOMAC a
  Stiffness     8 (0–12)    8 (0–14)
  Function  33 (8–58)  40 (3–60)
Duration of surgery, min a   60 (35–110)  50 (30–90)
Intraoperative bleeding, mL a  250 (50–750)  200 (50–1,100)
ª Median (range).
Table 4. Results for postoperative pain as primary endpoint, median (range)
  LINFA  Placebo  n (L/P) a  p-value b
   Pain scale  group  group
12 hours
  WOMAC  3.5 (0–7)    2.5 (0–5)  28/28  0.6
22 hours
  WOMAC     7 (2–15)       9 (0–13)  24/24  0.2
  NRS c     5 (1–16)       8 (0–18)  23/27  0.1
  WOMAC + NRS c   12 (3–30)     17 (0–31)  23/23  0.1
24 hours
  WOMAC     4 (0–12)       6 (0–10)  29/28  0.05 d
  NRS c     4 (0–14)       6 (0–17)  30/27  0.04 d
  WOMAC + NRS c     9 (0–23)  12.5 (0–26)  29/26  0.05 d
a n: number of registrations in the two groups (LINFA/placebo).
b Mann-Whitney U test.
c NRS pain (rest + activity)
d Adjustment of the p-values in the table in order to control the 
false discovery rate and so avoid spurious significant results due to 
multiple testing suggested that these results should be regarded as 
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Discussion
We found similar opioid consumption and postoperative pain 
scores in the LINFA group and the placebo group. Patients 
having  LIA  during  surgery  and  also  being  treated  with 
LINFA through a catheter 10 and 22 h after surgery were a 
priori expected to have less pain and/or reduced consumption 
of opioids than the placebo-treated patients. Those in both 
groups were given LIA during surgery. This may explain why 
no difference in pain was observed in the first 24 h after sur-
gery, as LIA may still be effective at this early postoperative 
period.
In a randomized, double-blind study Andersen et al. (2007b) 
investigated the effect of pain treatment with LIA combined 
with LINFA. Patients were randomized to receive either LIA 
combined with LINFA or saline administered during surgery 
and 24 h after THA surgery. The study involved 40 patients. 
A reduced consumption of Oxycodon on days 1–4 and also 
reduction in pain 4 h after surgery and for up to 2 weeks after 
surgery was found in the group receiving LIA combined with 
LINFA. 
In  another  randomized  and  double-blind  study  involving 
37 patients with THA and total knee arthroplasty, Bianconi et 
al. (2003) investigated the effect of LIA given during surgery 
in combination with 55 h of continuous LINFA administered 
through a catheter in the hip. This pain treatment was com-
pared with intravenous morphine treatment, and the conclu-
sion was that the consumption of additional analgesic 0–72 h 
after surgery was reduced; less pain was also reported 8–72 h 
after surgery in patients treated with LIA in combination with 
LINFA.
Andersen et al. (2007a) studied 80 THA patients to inves-
tigate the effect of LIA given during surgery in combination 
with LINFA (administered as 1 injection through a catheter 
to the hip 8 h after surgery). Pain treatment using LIA com-
bined with LINFA was compared with continuous epidural 
pain treatment, and there was less pain 24–96 h after surgery 
and reduced opioid consumption 0–96 hours after surgery in 
patients treated with LIA combined with LINFA.
It is not possible to compare the 3 studies above (Bianconi 
et al. 2003, Andersen et al. 2007a, b) directly with the present 
study, as their design differs. The 3 studies investigated the 
total effect of LIA given during surgery in combination with 
LINFA administered through a catheter as injections or con-
tinuous infusion after surgery. Our study, in which all patients 
in both groups received LIA during surgery, is the first to focus 
only on the effect of treatment with LINFA given after sur-
gery. We could not show the same positive effect of postopera-
tive LINFA on pain relief as the three other studies. This may 
be explained by the fact that pain treatment with LIA during 
surgery is highly effective, with an extended postoperative 
“hangover” pain-reducing effect, making postoperative treat-
ment with LINFA (administered through a catheter into the 
hip) of minor or no importance.
There was a higher proportion of women in the placebo 
group, which may have contributed to the findings of the dif-
ference in postoperative nausea and vomiting between the 2 
groups. It is well known that women are much more suscep-
tible to PONV than men (Gan et al. 2003).  
The median LOS in our study was 3 days for both groups, 
although the LINFA group had a slightly shorter LOS—but 
not statistically significantly. These LOS values are shorter 
than the LOS gathered on a national basis for 2004, which 
was mean 7.4 (4.6–10.9) days at that time (Husted et al. 2006).   
The reason why we can not find a statistically significant dif-
ference in LOS might be because the LOS already is very low 
and to reduce that even further it is required to make larger 
changes probably at the same time.
Our data were analyzed with an intention-to-treat approach. 
60 patients were included in the analysis, but there were 6 
breaches of protocol and the actual study group was 26 in the 
placebo group and 28 in the LINFA group. Thus, a per proto-
col analysis was done. The results from the per protocol analy-
sis were similar to those from the intention-to-treat results. 
163 patients were evaluated for participation in this study. 
Of  these,  103  were  immediately  excluded,  mainly  due  to 
preoperative use of opioids, surgery in general anesthesia, or 
treatment with different drugs that might possibly interfere 
with the study drugs. This may have weakened the final out-
come of the study, but in contrast it may have strengthened the 
Table 6. Results for PONV and tiredness in the LINFA and placebo groups, 
median (range)
  LINFA  Placebo  n (L/P) a    p-value b
  group  group 
Nausea + vomiting (EORTC)
  Day 0     1 (0–9)     2 (0–9)  30/30  0.1
  Day 1     0 (0–6)     2 (0–9)  30/30  < 0.001 c
  Day 2     0 (0–3)     1 (0–5)  30/30  0.001 c 
  Day 3     0 (0–8)     0 (0–4)  28/29  0.5
Nausea (NRS)
  Day 0  0.5 (0–8)  1.5 (0–10)  30/30  0.2
  Day 1     0 (0–8)     2 (0–9)  30/30  0.002 c
  Day 2     0 (0–2)  0.5 (0–6)  30/30  0.01 c
  Day 3     0 (0–10)     0 (0–6)  28/29  0.6
Nausea + vomiting (EORTC + NRS)
  Day 0  1.5 (0–17)  3.5 (0–19)  30/30  0.2
  Day 1     0 (0–13)     4 (0–17)  30/30  < 0.001 c
  Day 2     0 (0–5)  1.5 (0–10)  30/30  0.004 c
  Day 3     0 (0–18)     0 (0–9)  28/29  0.6
Tiredness (NRS)
  Day 0      3 (0–10)     4 (0–9)  29/29  0.7
  Day 1     3 (0–9)     4 (0–9)  30/30  0.04 d
  Day 2     2 (0–6)     3 (0–8)  30/30  0.08
  Day 3     2 (0–7)     2 (0–8)  28/28  0.3
a n: Number of registrations in the two groups (LINFA/placebo).
b Mann-Whitney U test.
c Statistically significant. 
d Adjustment of the p-values in the table in order to control the 
false discovery rate and so avoid spurious significant results due 
to multiple testing suggested that this result should be regarded as 
insignificant (Benjamini and Hochberg 1995).320  Acta Orthopaedica 2011; 82 (2): 315–320
“signal” in the patients under investigation where no possible 
bias from other medications could have arisen.  
In summary, we found some evidence of a short-term effect 
of LINFA on nausea and vomiting, but there was no evidence 
of an effect on postoperative pain and tiredness. Thus, LINFA 
cannot  be  recommended  as  a  standard  pain  treatment  in 
patients undergoing THA. 
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